Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 45

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 8
Chunk 45
---
 adoption of ASU 2023-09 will have on its financial statement disclosures.In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statement disclosures.

Note 4.    Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):December 31,20242023Savings and checking accounts at major U.S. financial institutions$428 $367 U.S. Treasury securities money market fund2,162 8,189 Total$2,590 $8,556 

Note 5.    Marketable Debt Securities

Marketable debt securities as of December 31, 2023 consisted entirely of U.S. Treasury bills purchased with maturities over three months but less than twelve months. There were no marketable debt securities as of December 31, 2024.

F-11

Note 6.    Prepaid Expenses

Prepaid expenses consisted of the following (in thousands):December 31,20242023Prepaid insurance$421 $647 Prepaid research and development costs239 — Prepaid other113 41 Total$773 $688 

Note 7.    Accrued Expenses

Accrued expenses consisted of the following (in thousands):December 31,20242023Accrued research and development costs$373 $439 Accrued employee compensation-related expenses56 392 Accrued other79 60 Total$508 $891 

Note